Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  The Yield Growth Corp.    BOSS   CA98584W2067

THE YIELD GROWTH CORP.

(BOSS)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

The Future of Mental Health Will be Led by Psychedelics

share with twitter share with LinkedIn share with facebook
06/24/2020 | 09:20am EDT

Houston, Texas--(Newsfile Corp. - June 24, 2020) - Psychedelics could soon revolutionize the way we treat mental health.

Already, several studies found such treatments can help treat obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, and anxiety. Psychiatrists at Johns Hopkins University even found that mushrooms can help with smoking cessation, and another study found it can assist with alcohol dependence.

Psilocybin and even LSD could also help treat eating disorders and obesity.

That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."

LSD Could Help Treat Obesity and Eating Disorders

Yield Growth's majority owned subsidiary NeonMind just filed an additional provisional patent application related to using psychedelics as medicine. The patent application covers the administration of a compound selected from the group consisting of lysergic acid diethylamide and d-lysergic acid amide (and compounds with similar molecular structure)in combination with a 5-HT2A antagonist to treat compulsive eating disorder, obesity and related illnesses.

The patent application was filed by NeonMind on June 5, 2020, and Translational Life Sciences Inc. has a 20% interest as a co-collaborator on the development of intellectual property. "Our research with our scientific team into using psilocybin to treat compulsive eating and food cravings has led to paths of inquiry for research into expanded medical uses of psychedelics," says Penny White, NeonMind CEO, "we are excited to lay the groundwork for new areas of potential research for the future."

Psilocybin Could be a Weight Loss Secret

In addition, NeonMind just filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin or psilocin (or analogs thereof) combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.

NeonMind previously announced that it filed a provisional patent in December 2019 for the use of microdose administration of Psilocybin for weight loss benefits. NeonMind has retained contract research organization Translational Life Sciences Inc. to design and plan an initial preclinical study using psilocybin which is anticipated to begin in the fall of 2020. The preclinical study is anticipated to provide data to design phase 2 human clinical trials to test Psilocybin as a weight loss treatment. The phase 2 clinical trials are anticipated to begin in 2021, subject to receiving all required regulatory approvals.

NeonMind's combined provisional patent applications cover the administration of Psilocybin to provide weight loss benefits and potential treatment or regulation of diabetes, and regulation of blood glucose, and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.

For more information, visit the company's website at https://yieldgrowth.com.

About MarijuanaStox

MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information:
2818047972
ty@marijuanastox.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58477


© Newsfilecorp 2020
share with twitter share with LinkedIn share with facebook
Latest news on THE YIELD GROWTH CORP.
07/02Three Ex-U.S. and Canada Cannabis Stocks to Consider for Your Portfolio -- CF..
NE
07/02This May be the Trick to Treating a Massive $16 Billion Weight Issue
NE
06/29YIELD GROWTH : Reports Voting Results of its 2020 Annual General Meeting
AQ
06/25Yield Growth Receives Health Canada Notification Numbers for 23 Plant-Based P..
NE
06/24Yield Growth Announces Financing
NE
06/24The Future of Mental Health Will be Led by Psychedelics
NE
06/23Yield Growth Announces New Canadian Distributor for its Urban Juve Products
NE
06/19These Psychedelic Drugs May Be Key to Revolutionizing Weight Loss Treatment
NE
06/18NeonMind Files Patent Application for Therapeutic Use of DMT
NE
06/17Much Like Cannabis, Support for Psilocybin Legalization is Gaining Support in..
NE
More news
Financials
Sales 2019 4,02 M 2,96 M 2,96 M
Net income 2019 -16,0 M -11,8 M -11,8 M
Net cash 2019 0,54 M 0,40 M 0,40 M
P/E ratio 2019 -1,43x
Yield 2019 -
Capitalization 14,3 M 10,5 M 10,5 M
EV / Sales 2018 -
EV / Sales 2019 6,43x
Nbr of Employees 19
Free-Float 67,2%
Chart THE YIELD GROWTH CORP.
Duration : Period :
The Yield Growth Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THE YIELD GROWTH CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 0,45 CAD
Last Close Price 0,10 CAD
Spread / Highest target 350%
Spread / Average Target 350%
Spread / Lowest Target 350%
EPS Revisions
Managers
NameTitle
Penny White President, Chief Executive Officer & Director
Tamara Melck Chief Operating Officer
Yu Cai Huang Chief Financial Officer
Spiros Margaris Independent Director
Amy Frankel Secretary, VP-People & General Counsel
Sector and Competitors
1st jan.Capitalization (M$)
THE YIELD GROWTH CORP.-47.37%11
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG4.71%295 898
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-10.36%192 057
PFIZER, INC.-11.92%191 697